Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers

ConclusionWe did not detect statistically significant changes in inflammatory markers in HSL skin of HS patients receiving apremilast compared with placebo, despite clinical improvement in the apremilast group. Nonetheless, S100A12 and IL ‐17A were significantly elevated in HSL skin and showed a decrease in response to apremilast. The translational model in clinical trials involving HS clearly needs further improvement.This article is protected by copyright. All rights reserved.

Source: Journal of the European Academy of Dermatology and Venereology - November 19, 2018 Category: Dermatology Authors: Allard R.J.V. Vossen, Hessel H. van der Zee, Nadine Davelaar, Adriana M.C. Mus, Martijn B.A. van Doorn, Errol P. Prens Tags: Short Report Source Type: research